{
    "clinical_study": {
        "@rank": "134586", 
        "acronym": "INFECIR2", 
        "arm_group": [
            {
                "arm_group_label": "Intravenous  infusion", 
                "arm_group_type": "Experimental", 
                "description": "Treatment arm will received intravenous albumin on day 1 and 3"
            }, 
            {
                "arm_group_label": "No treatment", 
                "arm_group_type": "No Intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to evaluate whether  albumin administration improves short-term\n      survival in patients with advanced cirrhosis, signs of systemic inflammation and bacterial\n      infections other than Spontaneous Bacterial Peritonitis (SBP)."
        }, 
        "brief_title": "The INFECIR-2 Albumin Prevention Study", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Advanced Chronic Liver Disease", 
            "Urinary Infection", 
            "Pneumonia", 
            "Cholangitis", 
            "Other Bacterial Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bacterial Infections", 
                "Cholangitis", 
                "Hepatorenal Syndrome", 
                "Liver Diseases", 
                "Pneumonia", 
                "Urinary Tract Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "The aim of this study is to evaluate if IV albumin administration improves short-term\n      survival in patients with advanced cirrhosis (serum creatinine \u2265 1.2 mg/dl, serum sodium \u2264\n      130 mEq/l -milliequivalents per liter- and/or serum bilirubin \u22654 mg/dl), signs of systemic\n      inflammation and bacterial infections other than spontaneous bacterial peritonitis (urinary\n      infection, pneumonia, skin/soft tissue infection, acute cholangitis or suspected bacterial\n      infection).\n\n      Primary goals of the study:\n\n      \u2022 Effect of albumin administration 28-day survival and in hospital survival (average 2\n      weeks).\n\n      Secondary goals of the study:\n\n        -  Effect of albumin administration on 90-day survival.\n\n        -  Effect of albumin administration on the incidence of renal dysfunction, type-1 and 2\n           Hepatorenal Syndrome (HRS) during hospitalization.\n\n        -  Effect of albumin on circulatory function estimated by changes in plasma levels of\n           renin and noradrenaline and in serum levels of lactate among infection diagnosis, day 3\n           and infection resolution.\n\n        -  Effect of albumin on serum levels of interleukin-6 (IL-6), tumor necrosis factor alpha\n           (TNF-alpha) and nitric oxide (NOX) and on plasma levels of von Willebrand factor\n           (vWF:Ag) at diagnosis and resolution of infection.\n\n        -  Effect of albumin on blood leukocyte count and serum C-reactive protein levels (CRP)\n           during infection.\n\n        -  Effect of albumin on the development of other individual organ failures (renal, liver,\n           cerebral, circulatory, coagulation and respiratory), acute-on-chronic liver failure\n           (ACLF type 1, 2 and 3 according to the Canonic Study), CLIF-SOFA score, CLIF-Consortium\n           score, Child-Pugh score and MELD score during hospitalization.\n\n        -  Evaluation of predictive factors of HRS and ACLF development in non-SBP infections.\n\n        -  Samples (blood, plasma, serum and urine) will be obtained and stored for genomic,\n           proteomic and standard biochemical investigations in future ancillary studies related\n           to the aim of the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Cirrhotic patients with age between 18 and 79 years\n\n          -  Signs of systemic inflammation: at least 1 diagnostic criterion of systemic\n             inflammatory response syndrome (SIRS) and serum CRP levels \u22652 mg/dl (20 mg/L). This\n             CRP cut-off value has a 82% sensitivity and a 70% specificity for the diagnosis of\n             bacterial infection in advanced cirrhosis\n\n          -  Urinary infection, pneumonia, skin/soft tissue infection, acute cholangitis or\n             suspected bacterial infection\n\n          -  Analytical data of renal and/or liver dysfunction (serum creatinine \u2265 1.2 mg/dl,\n             serum sodium \u2264 130 mEq/l, serum bilirubin \u22654 mg/dl). Patients with pneumonia will\n             require the presence of at least 1 of these analytical criteria to be included in the\n             study. Patients with urinary infection, skin/soft tissue infection, acute cholangitis\n             or suspected bacterial infection will require 2 or more criteria for inclusion\n\n        Exclusion Criteria:\n\n          -  > 48h after infection diagnosis\n\n          -  Pregnancy\n\n          -  Acute or subacute liver failure without underlying cirrhosis\n\n          -  Septic shock\n\n          -  Acute respiratory distress syndrome\n\n          -  Gastrointestinal bleeding in the last 5 days\n\n          -  Biopsy proven severe acute alcoholic hepatitis requiring specific treatment\n\n          -  Type-3 ACLF (defined according to the Canonic Study criteria)\n\n          -  Type-1 HRS (IAC criteria; serum creatinine \u2265 2.5 mg/dl)\n\n          -  Intrinsic nephropathy with renal failure (serum creatinine chronically \u2265 1.5 mg/dl)\n\n          -  Hemodialysis or other renal replacement therapy\n\n          -  Arterial hypertension (systolic blood pressure > 160 mmHg and/or diastolic blood\n             pressure > 90 mmHg)\n\n          -  Evidence of current malignancy (except for hepatocellular carcinoma within Milan\n             criteria or non-melanocytic skin cancer)\n\n          -  Moderate or severe chronic heart (NYHA class II, III or IV) or pulmonary disease\n             (GOLD III or IV)\n\n          -  Severe psychiatric disorders\n\n          -  Immunosuppressive drugs\n\n          -  HIV infection\n\n          -  Contraindications to albumin (allergy, signs of pulmonary edema)\n\n          -  Administration of any dose of IV albumin in the last 10 days\n\n          -  Clinical indication for albumin use at inclusion (spontaneous bacterial peritonitis\n             coinfection, large volume paracentesis)\n\n          -  Refusal to participate\n\n          -  Patients who cannot provide prior informed consent and when there is documented\n             evidence that the patient has no legal surrogate decision maker and it appears\n             unlikely that the patient will regain consciousness or sufficient ability to provide\n             delayed informed consent\n\n          -  Physician and team not committed to intensive care if needed."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "79 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "512", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02034279", 
            "org_study_id": "INFECIR 2", 
            "secondary_id": "2013-002416-27"
        }, 
        "intervention": {
            "arm_group_label": "Intravenous  infusion", 
            "intervention_name": "Albumin", 
            "intervention_type": "Drug", 
            "other_name": "Albutein 20 by Grifols"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "cirrhosis", 
        "lastchanged_date": "January 10, 2014", 
        "link": {
            "url": "http://www.clifconsortium.com/"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Barcelona", 
                    "country": "Spain", 
                    "zip": "08036"
                }, 
                "name": "Hospital Clinic"
            }, 
            "investigator": {
                "last_name": "Javier Fernandez, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Albumin Administration in the Prevention of Hepatorenal Syndrome and Death in Patients With Cirrhosis, Bacterial Infections Other Than Spontaneous Bacterial Peritonitis and High Risk of Hospital Mortality", 
        "overall_contact": {
            "email": "jdez@clinic.ub.es", 
            "last_name": "Javier Fernandez, PhD", 
            "phone": "0034932270000", 
            "phone_ext": "2204"
        }, 
        "overall_contact_backup": {
            "email": "rigarcia@clinic.ub.es", 
            "last_name": "Rita Garcia, PhD", 
            "phone": "0034932271826"
        }, 
        "overall_official": [
            {
                "affiliation": "Erasme University Hospital, Brussels, Belgium", 
                "last_name": "Thierry Gustot", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University Hospitals KU, Leuven, Belgium", 
                "last_name": "Frederick Nevens", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "H\u00f4pital Paul Brousse, Villejuif, France", 
                "last_name": "Faouzi Saliba", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "H\u00f4pital Beaujon, Clichy, France", 
                "last_name": "Fran\u00e7ois Durand", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Ulm, Heidelberg and T\u00fcbingen, Germany", 
                "last_name": "Matthias Dollinger", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University Hospital of Frankfurt, Germany", 
                "last_name": "Stefan Zeuzem", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University Hospital of Munich, Germany", 
                "last_name": "Alexander Gerbes", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University Hospital of Bonn, Germany", 
                "last_name": "Jonel Trebicka", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Aarhus University Hospital, Aarhus, Denmark", 
                "last_name": "Henning Gronbaeck", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Rigshospitalet, University of Copenhagen", 
                "last_name": "Fin Stolze Larsen", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Oslo University Hospital, Norway", 
                "last_name": "Zbigniew Konopski", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Bern University Hospital, Switzerland", 
                "last_name": "Andrea de Gottardi", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University College of Dublin, Ireland", 
                "last_name": "Aide McCormick", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University College London, United Kingdom", 
                "last_name": "Rajiv Jalan", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Santa Orsola-Malpighi Hospital, Bologna, Italy", 
                "last_name": "Mauro Bernardi", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Padova, Italy", 
                "last_name": "Paolo Angeli", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "San Giovanni Battista Hospital, University of Turin, Italy", 
                "last_name": "Carlo Alessandria", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Policlinico IRCCS San Donato, University of Milan, Italy", 
                "last_name": "Francesco Salerno", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Ramon y Cajal, Madrid, Spain", 
                "last_name": "Agustin Albillos", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Vall d'Hebron, Barcelona, Spain", 
                "last_name": "Juan Cordoba", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Clinic, Barcelona, Spain", 
                "last_name": "Javier Fernandez", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Santa Creu i Sant Pau, Barcelona, Spain", 
                "last_name": "German Soriano", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Gregorio Mara\u00f1on, Madrid, Spain", 
                "last_name": "Rafael Ba\u00f1ares", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Reina Sofia, Cordoba, Spain", 
                "last_name": "Jose Luis Montero", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Sapienza University of Rome, Italy", 
                "last_name": "Manuela Merli", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "28-day survival and in hospital survival (expected average 2 weeks) will be the primary outcome", 
            "measure": "survival", 
            "safety_issue": "Yes", 
            "time_frame": "28-day survival"
        }, 
        "reference": {
            "PMID": "22732511", 
            "citation": "Guevara M, Terra C, Nazar A, Sol\u00e0 E, Fern\u00e1ndez J, Pavesi M, Arroyo V, Gin\u00e8s P. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol. 2012 Oct;57(4):759-65. doi: 10.1016/j.jhep.2012.06.013. Epub 2012 Jun 23."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02034279"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percentage of subjects within each arm that survived at this time point", 
                "measure": "survival", 
                "safety_issue": "Yes", 
                "time_frame": "90-day survival"
            }, 
            {
                "description": "number of participants", 
                "measure": "Renal dysfunction", 
                "safety_issue": "Yes", 
                "time_frame": "hospitalization (expected average 2 weeks)"
            }, 
            {
                "description": "plasma concentration of hormones", 
                "measure": "circulatory dysfunction", 
                "safety_issue": "Yes", 
                "time_frame": "day 3 and day of infection resolution"
            }, 
            {
                "description": "Plasma concentration of citokines", 
                "measure": "Inflammation and endothelial function", 
                "safety_issue": "Yes", 
                "time_frame": "day of infection resolution"
            }, 
            {
                "description": "number of organ failures", 
                "measure": "subsequent organ failure", 
                "safety_issue": "Yes", 
                "time_frame": "hospitalization (expected average 2 weeks)"
            }
        ], 
        "source": "EASL - CLIF Consortium", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "EASL - CLIF Consortium", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}